Showing results (81-90 of 114) with videos related to
Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 2006
Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II studyM Montemurro, T Kiefer, F Schüler, et al.Journal of Clinical Medicine|July 28, 2026
Sleep Disturbances, Metabolic Markers, and Outcomes After Stroke: A Retrospective Cohort Study in a Tertiary HospitalFahad Alkhamis, Majed M Alabdali, Danah Aljaafari, et al.British Journal of Haematology|May 23, 2013
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077Wolfram Pönisch, Simone Heyn, Juliane Beck, et al.Annals of Hematology|July 29, 2024
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patientsStefanie Jilg, Juliana Schwaab, Katja Sockel, et al.Current Medical Research and Opinion|February 1, 2018
Hemoglobin A2 (HbA2) has a measure of unreliability in diagnosing β-thalassemia trait (β-TT)Amani M Al-Amodi, Neda Z Ghanem, Sumayh A Aldakeel, et al.Molecular Medicine Reports|November 16, 2017
The ‑α3.7 deletion in α‑globin genes increases the concentration of fetal hemoglobin and hemoglobin A2 in a Saudi Arabian populationJ Francis Borgio, Sayed Abdulazeez, Noor B Almandil, et al.Leukemia|April 1, 2005
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CMLF R Kerbauy, R Storb, U Hegenbart, et al.Human Genomics|December 21, 2022
Whole-exome sequencing of a Saudi epilepsy cohort reveals association signals in known and potentially novel lociAbdulrahman H Al Anazi, Ahmed S Ammar, Mahmoud Al-Hajj, et al.Drug Metabolism and Personalized Therapy|April 6, 2022
Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setupAbdullah M Al-Rubaish, Fahad A Al-Muhanna, Abdullah M Alshehri, et al.Drug Metabolism and Personalized Therapy|July 8, 2021
Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setupAbdullah M Al-Rubaish, Fahad A Al-Muhanna, Abdullah M Alshehri, et al.Pageof 12